Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.46 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.43 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | MME | P08473 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | CPA1 | P15085 | 1/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7541479 | 0.87 | ADRB2 (0.47) | PPARGLTA4HNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7344073 | 0.83 | PPARG (0.62) | PPARGLTA4HNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7544099 | 0.83 | L3MBTL1 (0.47) | PPARGLTA4HNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7338154 | 0.81 | PPARG (0.51) | PPARGLTA4HNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7547521 | 0.80 | KMT2A (0.48) | PPARGSMN1; SMN2 | |
| SCHEMBL7345222 | 0.80 | PPARG (0.51) | PPARGLTA4HNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7346029 | 0.79 | PPARG (0.49) | PPARGLTA4HNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7339686 | 0.79 | PPARG (0.49) | PPARGLTA4HNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7337025 | 0.79 | KLKB1 (0.52) | PPARGMMEACECPA1ACE2 | |
| SCHEMBL7338315 | 0.79 | PPARG (0.52) | PPARGLTA4HNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6362174-B1 | ANALGESICS, ANTIISCHEMIC AGENTS, ANTIEOILEPTIC AGENTS | WARNER-LAMBERT COMPANY | 2002-03-26 | — | — | US | claimed |
| US-20020028801-A1 | Reduced dipeptide analogues as calcium channel antagonitsts | RAFFERTY MICHAEL FRANCIS (US) | 2002-03-07 | — | — | US | claimed |
| US-6316440-B1 | TREATMENT OF STROKE, HEAD TRAUMA, CEREBRAL ISCHEMIA, PAIN AND EPILEPSY | WARNER-LAMBERT COMPANY | 2001-11-13 | — | — | US | claimed |
| US-6362174-B1 | ANALGESICS, ANTIISCHEMIC AGENTS, ANTIEOILEPTIC AGENTS | WARNER-LAMBERT COMPANY | 2002-03-26 | — | — | US | disclosed |
| US-20020028801-A1 | Reduced dipeptide analogues as calcium channel antagonitsts | RAFFERTY MICHAEL FRANCIS (US) | 2002-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028801-A1 | Reduced dipeptide analogues as calcium channel antagonitsts | CACNA1E, RYR1, CACNA1B | PPARG 4719/4885LPAR1 961/4885LPAR3 835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.